Acrivon Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Net loss for the quarter ended September 30, 2026, was $17.9 million, compared to a net loss of $18.2 million for the same period in 2025.
- Research and development expenses were $14.5 million for the quarter, an increase from $13.6 million in the same period in 2025, driven by the timing of clinical trial and related costs for ACR-368 and ACR-2316.
- General and administrative expenses were $4.0 million for the quarter, a decrease from $6.0 million in the same period in 2025, primarily due to lower employee-related expenses including stock-based compensation.
- Cash, cash equivalents, and marketable securities totaled $77.8 million as of September 30, 2026, expected to fund operations into the fourth quarter of 2027.
- Total operating expenses for the nine months ended September 30, 2026, were $57.1 million, down from $64.0 million in the same period in 2025.
- Net loss for the nine months ended September 30, 2026, was $54.9 million, compared to $58.9 million in the same period in 2025.
- Net loss per share (basic and diluted) was $0.42 for the quarter ended September 30, 2026, compared to $0.47 in the same period in 2025.
Guidance and Future Outlook:
- A prespecified Phase 2b interim analysis of ACR-368 in all-comer serous endometrial cancer treatment arms is expected in the fourth quarter of 2026.
- Complete enrollment of the registrational intent all-comer serous EC Arm 3 or Arm 4 for ACR-368 is expected in the fourth quarter of 2026.
- ACR-2316 is expected to complete enrollment in the dose expansion phase and generate additional data to prioritize the Phase 2 registrational path by mid-2027.
- An Investigational New Drug (IND) filing for ACR-7280 is targeted for the first half of 2027.
- FDA alignment on trial design for the Phase 2 Eosinophilic Esophagitis (EoE) study for ACR-525 is expected in the first quarter of 2027.
- Promising lead candidates for the PKCθ program are expected to advance towards IND-enabling studies in the first half of 2027.
Business Segments and Product Lines:
- Immunology and Inflammation (I&I) established as a second strategic pillar alongside oncology.
- Acquired ACR-525, a Phase 2-ready, oral, highly selective JAK1 inhibitor identified via the AI-driven AP3 platform, with Eosinophilic Esophagitis (EoE) targeted as the first indication.
- ACR-525 demonstrated favorable safety in two Phase 1 studies in healthy volunteers with no serious adverse events and dose-dependent inhibition of CXCL10.
- Acquired a preclinical PKCθ inhibitor program targeting T-cell activation in I&I disorders.
- ACR-368 (CHK1/2 inhibitor) dosing continues in U.S. and European sites for the registrational-intent Phase 2b study in serous endometrial cancer.
- ACR-2316 (WEE1/PKMYT1 inhibitor) showed long-lasting clinical benefit and confirmed complete and partial responses in heavily pretreated, AP3-predicted tumor types including lung and endometrial cancers during Phase 1/2 dose escalation.
- ACR-2316 demonstrated a favorable safety profile limited primarily to transient, asymptomatic, mechanism-based neutropenia.
- ACR-2316 is being tested as a single agent in pancreatic ductal adenocarcinoma based on synthetic lethality in K-Ras & p53 mutated contexts.
- ACR-7280 (CDK11 inhibitor) is in IND-enabling studies for Acute Myeloid Leukemia (AML) and peripheral T-cell lymphoma, with preclinical data showing complete tumor regression in aggressive AML models.
Market and Competitive Landscape:
- ACR-525 profiling showed favorable selectivity and attractive pathway effects compared to approved JAK inhibitors and dupilumab, preventing IL-13-driven esophageal epithelial barrier dysfunction.
- ACR-2316 data presented at the 38th EORTC-NCI-AACR Symposium highlights its differentiated mechanism and superior therapeutic index compared to current single-agent WEE1 or PKMYT1 inhibitors.
- ACR-2316 demonstrates strong synergy with immune checkpoint inhibitors and Topo1 inhibitors.
- ACR-7280 demonstrated strong synergy with BCL-2 and menin inhibitors in preclinical studies.
Risks and Challenges:
- The press release includes standard forward-looking statement disclosures noting that actual results may differ due to inherent uncertainties, risks, and assumptions.
- Specific risks include those described in the company's reports filed with the Securities and Exchange Commission, though specific risk factors are not detailed in the text.
Management Commentary and Tone:
- CEO Peter Blume-Jensen described the year's progress as "transformative," highlighting the strategic expansion into I&I and positive clinical results for ACR-2316.
- Management expressed confidence that the I&I segment is "particularly well-suited" for the AP3 precision medicine approach.
- CEO noted that ACR-525 was identified as a "potentially best-in-class" JAK1 inhibitor through AI-driven profiling.
- Management highlighted "exciting data" regarding ACR-2316, including patients on treatment for over 73 weeks and confirmed complete responses in heavily pretreated lung cancers.
- The tone is optimistic regarding upcoming value-inflection milestones and the potential for multiple indications across oncology and I&I.
Other Key Points:
- ACR-2316 data will be presented as a late-breaking oral plenary presentation at the 38th EORTC-NCI-AACR Symposium by Dr. Timothy A. Yap.
- ACR-525 is formulated as a tablet for oral suspension specifically designed for patients with difficulty swallowing.
- ACR-368 has received Fast Track designation from the FDA for monotherapy investigation based on OncoSignature-predicted sensitivity.
- The FDA granted Breakthrough Device designation for the ACR-368 OncoSignature assay.
- ACR-2316 showed activity in molecularly-defined lung, endometrial, ovarian, cervical, and esophago-gastric junction cancers.
- ACR-2316 has observed long-lasting clinical benefit (over one year) in subjects with lung adenocarcinoma.
- ACR-7280 was prioritized among multiple AP3-discovered CDK11 inhibitor candidates based on potent single-agent activity.
- The company held a corporate webcast with EoE Key Opinion Leaders to review ACR-525 data.
- Company
- ACRIVON THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology